Genprex, Inc., based in Austin, TX, has announced the initiation of a Phase 1/2 clinical trial for Quaratusugene Ozeplasmid gene therapy combined with Atezolizumab maintenance therapy in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). This study aims to evaluate the efficacy and safety of the TUSC2 gene encapsulated in lipid-based nanoparticles. The trial will include patients who have shown a complete response, partial response, or stable disease after receiving three to four cycles of standard treatment, which includes atezolizumab, carboplatin, and etoposide. The study's design and methodology include a futility analysis after the 25th patient reaches 18 weeks of follow-up, with patient eligibility criteria focusing on those with an ECOG Performance Status of 0 to 1. Further details are available on Genprex's official website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.